Immunity against tumor angiogenesis induced by a fusion vaccine with murine β-defensin 2 andmFlk-1

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages 6779-6787

  Wang, Yong Sheng ^a   Wang, Guo Qing ^a   Wen, Yan Jun ^a   Wang, Lian ^a   Chen, Xian Cheng ^a,b   Chen, Ping ^a   Kan, Bin ^a   Li, Jiong ^a   Huang, Canhua ^a   Lu, You ^a   Zhou, Qin ^a   Xu, Ning ^a   Li, Dan ^a   Fan, Ling Yu ^a   Yi, Tao ^a,b   Wu, Hong Bo ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; AUTOANTIBODY; BETA DEFENSIN 2; DNA VACCINE; METHYL CPG BINDING PROTEIN 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ASSAY; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE MODEL; ENDOTHELIUM CELL; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STIMULATION; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; BETA-DEFENSINS; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; ENDOTHELIUM, VASCULAR; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 36749026293     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1587     Document Type: Article

References (40)

1. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
3. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39:469-78.
4. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol 2005;18:485-94.
5. Weigand M, Hantel P, Kreienberg R, Waltenberger J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 2005;8:197-204.
6. Lacal PM, Ruffini F, Pagani E, D'Atri S. An autocrine loop directed byt he vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol 2005;27:1625-32.
7. Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000;106:511-21.
8. Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D. VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003;22:3361-70.
9. Ribatti D, Vacca A. Novel therapeutic approaches targeting vascular endothelial growth factor and its receptors in haematological malignancies. Curr Cancer Drug Targets 2005;5:573-8.
10. Strawn LM, McMahon G, App H, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996;56:3540-5.
11. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000;60:5117-24.
12. Liu JY, Wei YQ, Yang L, et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003;102:1815-23.
13. Zhu Z, Hattori K, Zhang H, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibodyaffinity and biological activity. Leukemia 2003;17:604-11.
14. Zhou H, Luo Y, Mizutani M, Mizutani N, Reisfeld RA, Xiang R. Tcell-mediated suppression of angiogenesis results in tumor protective immunity. Blood 2005;106:2026-32.
15. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000;18:927-74.
16. Stevenson FK, Rice J, Ottensmeier CH, Thirdborough SM, Zhu D. DNA fusion gene vaccines against cancer: from the laboratoryto the clinic. Immunol Rev 2004;199:156-80.
17. Coscia M, Biragyn A. Cancer immunotherapy with chemoattractant peptides. Semin Cancer Biol 2004;14:209-18.
18. Hauser H, Shen L, Gu QL, Krueger S, Chen SY. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther 2004;11:924-32.
19. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999;17:253-8.
20. An LL, Yang YH, Ma XT, et al. LL-37 enhances adaptive antitumor immune response in a murine model when genetically fused with M-CSFR (J6-1) DNA vaccine. Leuk Res 2005;29:535-43.
21. Biragyn A, Kwak LW. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions. Immunol Rev 1999;170:115-26.
22. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004;4:469-78.
23. + T-cell responses. Blood 2006;107:4597-605.
24. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 2002;298:1025-9.
25. Biragyn A, Surenhu M, Yang D, et al. Mediators of innate immunityt hat target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001;167:6644-53.
26. Yang D, Chertov O, Bykovskaia SN, et al. β-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science1999;286:525-8.
27. Nair S, McLaughlin C, Weizer A, et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003;171:6275-82.
28. Li G, Tian L, Hou JM, et al. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res 2005;11:4217-24.
29. Howard OM, Dong HF, Su SB, et al. Autoantigens signal through chemokine receptors: uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrate. Blood 2005;105:4207-14.
30. He QM, Wei YQ, Tian L, et al. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 2003;278:21831-6.
31. Hoffmann J, Schirner M, Menrad A, Schneider MR. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res 1997;57:3847-51.
32. Yi T, Wei YQ, Tian L, et al. Humoral and cellular immunityi nduced by tumor cell vaccine based on the chicken xenogeneic homologous matrix metalloproteinase-2. Cancer Gene Ther 2006;14:158-64.
33. Lucas PJ, Kim SJ, Mackall CL, et al. Dysregulation of IL-15-mediated T-cell homeostasis in TGF-β dominant-negative receptor transgenic mice. Blood 2006;108:2789-95.
34. Horton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE. A gene therapyf or cancer using intramuscular injection of plasmid DNA encoding interferon α. Proc Natl Acad Sci U S A 1999;96:1553-8.
35. Sallusto F, Palermo B, Lenig D, et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999;29:1617-25.
36. Vajkoczy P , Farhadi M, Gaumann A, et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002;109:777-85.
37. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998;91:3527-61.
38. Xue C, Wyckoff J, Liang F, et al. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 2006;66:192-7.
39. Zhang L, Kharbanda S, McLeskey SW, Kern FG. Overexpression of fibroblast growth factor 1 in MCF-7 breast cancer cells facilitates tumor cell dissemination but does not support the development of macrometastases in the lungs or lymph nodes. Cancer Res 1999;59:5023-9.
40. Li Y, Wang MN, Li H, et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 2002;195:1575-84.